Trial · NCT02981407
Myocardial Ischemia and Transfusion
NCT02981407, Phase 3, Completed, Rutgers, The State University of New Jersey; results first posted 2024-05-09
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. Myocardial Ischemia and Transfusion. Trials, record NCT02981407. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02981407
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Myocardial Ischemia and Transfusion
- NCT number
- NCT02981407
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 3,506 participants, actual
- Lead sponsor
- Rutgers, The State University of New Jersey
- Conditions
- Myocardial Infarction, Anemia
- Interventions
- Red Blood Cell Transfusion
- First posted
- 2016-12-05
- Last updated
- 2024-05-09
- Results first posted
- 2024-05-09
Source ClinicalTrials.gov
Registered outcomes19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With All-cause Mortality or Nonfatal Myocardial Reinfarction | Within 30 days of randomization | |
| Secondary | All-cause Mortality | Within 30 days of randomization | |
| Secondary | Myocardial Reinfarction | Within 30 days of randomization | |
| Secondary | Composite of All-cause Mortality, Nonfatal Myocardial Reinfarction, Ischemia Driven Unscheduled Coronary Revascularization, or Readmission to the Hospital for Ischemic Cardiac Diagnosis | Within 30 days of randomization | |
| Other | Composite of All-cause Mortality,Nonfatal Myocardial Reinfarction, or Unstable Angina | Within 30 days of randomization | |
| Other | Ischemia Driven Unscheduled Coronary Revascularization | Within 30 days of randomization | |
| Other | Unscheduled Readmission to Hospital for Ischemic Cardiac Diagnosis | Within 30 days of randomization | |
| Other | Heart Failure | Within 30 days of randomization | |
| Other | Unscheduled Readmission to Hospital for Any Reason | Within 30 days of randomization | |
| Other | Stroke | Within 30 days of randomization |
1 to 10 of 19Source ClinicalTrials.gov
See all 19 registered outcomesOutcomes19
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With All-cause Mortality or Nonfatal Myocardial Reinfarction | Within 30 days of randomization | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | All-cause Mortality | Within 30 days of randomization | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Myocardial Reinfarction | Within 30 days of randomization | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Composite of All-cause Mortality, Nonfatal Myocardial Reinfarction, Ischemia Driven Unscheduled Coronary Revascularization, or Readmission to the Hospital for Ischemic Cardiac Diagnosis | Within 30 days of randomization | Participants | COUNT_OF_PARTICIPANTS | |
| OTHER_PRE_SPECIFIED | Composite of All-cause Mortality,Nonfatal Myocardial Reinfarction, or Unstable Angina | Within 30 days of randomization | Participants | COUNT_OF_PARTICIPANTS | |
| OTHER_PRE_SPECIFIED | Ischemia Driven Unscheduled Coronary Revascularization | Within 30 days of randomization | Participants | COUNT_OF_PARTICIPANTS | |
| OTHER_PRE_SPECIFIED | Unscheduled Readmission to Hospital for Ischemic Cardiac Diagnosis | Within 30 days of randomization | |||
| OTHER_PRE_SPECIFIED | Heart Failure | Within 30 days of randomization | Participants | COUNT_OF_PARTICIPANTS | |
| OTHER_PRE_SPECIFIED | Unscheduled Readmission to Hospital for Any Reason | Within 30 days of randomization | |||
| OTHER_PRE_SPECIFIED | Stroke | Within 30 days of randomization | Participants | COUNT_OF_PARTICIPANTS |
1 to 10 of 19Source ClinicalTrials.gov
See all 19 outcomesResults by group18
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With All-cause Mortality or Nonfatal Myocardial Reinfarction | Liberal Transfusion Strategy | 255 | Participants | ||
| Number of Participants With All-cause Mortality or Nonfatal Myocardial Reinfarction | Restrictive Transfusion Strategy | 295 | Participants | ||
| All-cause Mortality | Liberal Transfusion Strategy | 146 | Participants | ||
| All-cause Mortality | Restrictive Transfusion Strategy | 173 | Participants | ||
| Myocardial Reinfarction | Liberal Transfusion Strategy | 126 | Participants | ||
| Myocardial Reinfarction | Restrictive Transfusion Strategy | 149 | Participants | ||
| Composite of All-cause Mortality, Nonfatal Myocardial Reinfarction, Ischemia Driven Unscheduled Coronary Revascularization, or Readmission to the Hospital for Ischemic Cardiac Diagnosis | Liberal Transfusion Strategy | 305 | Participants | ||
| Composite of All-cause Mortality, Nonfatal Myocardial Reinfarction, Ischemia Driven Unscheduled Coronary Revascularization, or Readmission to the Hospital for Ischemic Cardiac Diagnosis | Restrictive Transfusion Strategy | 342 | Participants | ||
| Composite of All-cause Mortality,Nonfatal Myocardial Reinfarction, or Unstable Angina | Liberal Transfusion Strategy | 300 | Participants | ||
| Composite of All-cause Mortality,Nonfatal Myocardial Reinfarction, or Unstable Angina | Restrictive Transfusion Strategy | 338 | Participants |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 results by groupParticipant flow8
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Liberal Transfusion Strategy | 1,757 | |
| Overall Study | STARTED | Restrictive Transfusion Strategy | 1,749 | |
| Overall Study | Data at 30 Days Post Randomization | Liberal Transfusion Strategy | 1,755 | |
| Overall Study | Data at 30 Days Post Randomization | Restrictive Transfusion Strategy | 1,749 | |
| Overall Study | COMPLETED | Liberal Transfusion Strategy | 1,755 | |
| Overall Study | COMPLETED | Restrictive Transfusion Strategy | 1,749 | |
| Overall Study | NOT COMPLETED | Liberal Transfusion Strategy | 2 | |
| Overall Study | NOT COMPLETED | Restrictive Transfusion Strategy | 0 |
Source ClinicalTrials.gov
Adverse events44
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Atrial Fibrillation | Cardiac disorders | Liberal Transfusion Strategy | 187 | 1,755 | 187 |
| other | Atrial Fibrillation | Cardiac disorders | Restrictive Transfusion Strategy | 194 | 1,749 | 194 |
| other | Stable Angina | Cardiac disorders | Liberal Transfusion Strategy | 183 | 1,755 | 183 |
| other | Stable Angina | Cardiac disorders | Restrictive Transfusion Strategy | 176 | 1,749 | 186 |
| serious | Myocardial Infarction | Cardiac disorders | Liberal Transfusion Strategy | 126 | 1,755 | 126 |
| serious | Myocardial Infarction | Cardiac disorders | Restrictive Transfusion Strategy | 149 | 1,749 | 149 |
| serious | Heart Failure | Cardiac disorders | Liberal Transfusion Strategy | 111 | 1,755 | 111 |
| serious | Heart Failure | Cardiac disorders | Restrictive Transfusion Strategy | 102 | 1,749 | 102 |
| serious | Super ventricular tachycardia | Cardiac disorders | Liberal Transfusion Strategy | 28 | 1,755 | 28 |
| serious | Super ventricular tachycardia | Cardiac disorders | Restrictive Transfusion Strategy | 27 | 1,749 | 27 |
1 to 10 of 44Source ClinicalTrials.gov
See all 44 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Liberal Transfusion Strategy | 353 | 1,755 |
| Total, all-cause mortality | Restrictive Transfusion Strategy | 376 | 1,749 |
| Total, other adverse events | Liberal Transfusion Strategy | 330 | 1,755 |
| Total, other adverse events | Restrictive Transfusion Strategy | 348 | 1,749 |
| Total, serious adverse events | Liberal Transfusion Strategy | 699 | 1,755 |
| Total, serious adverse events | Restrictive Transfusion Strategy | 723 | 1,749 |
Source ClinicalTrials.gov
Papers21
The papers the trial lists on ClinicalTrials.gov.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| U01HL133817 | Myocardial Ischemia and Transfusion (MINT) - CCC | CARSON, JEFFREY LEE | RUTGERS BIOMEDICAL AND HEALTH SCIENCES | NATIONAL HEART, LUNG, AND BLOOD INSTITUTE | 2016 to 2022 |
Source NIH RePORTER
Trial comparisons11
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Liberal Transfusion Strategy vs Restrictive Transfusion Strategy: Myocardial Reinfarction | Trial comparisons |
Liberal Transfusion Strategy vs Restrictive Transfusion Strategy: Composite of All-cause Mortality, Nonfatal Myocardial Reinfarction, Ischemia Driven Unscheduled Coronary Revascularization, or Readmission to the Hospital for Ischemic Cardiac Diagnosis | Trial comparisons |
| Liberal Transfusion Strategy vs Restrictive Transfusion Strategy: Pulmonary Embolism or Deep Venous Thrombosis | Trial comparisons |
| Liberal Transfusion Strategy vs Restrictive Transfusion Strategy: Ischemia Driven Unscheduled Coronary Revascularization | Trial comparisons |
| Liberal Transfusion Strategy vs Restrictive Transfusion Strategy: Composite of All-cause Mortality,Nonfatal Myocardial Reinfarction, or Unstable Angina | Trial comparisons |
| Liberal Transfusion Strategy vs Restrictive Transfusion Strategy: All-cause Mortality | Trial comparisons |
| Liberal Transfusion Strategy vs Restrictive Transfusion Strategy: Number of Participants With All-cause Mortality or Nonfatal Myocardial Reinfarction | Trial comparisons |
| Liberal Transfusion Strategy vs Restrictive Transfusion Strategy: Stroke | Trial comparisons |
| Liberal Transfusion Strategy vs Restrictive Transfusion Strategy: Heart Failure | Trial comparisons |
| Liberal Transfusion Strategy vs Restrictive Transfusion Strategy: deaths from any cause | Trial comparisons |
1 to 10 of 11
See all 11 trial comparisonsTests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02981407
GET https://conductscience.org/api/trials/v1/NCT02981407/events?page=2